Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
memantine lozenge FP01
- Development stage
- Discontinued
- Lead developer
- Avalo Therapeutics
- Modality
- Device-based Delivery → Drug Delivery Systems, Small Molecules
- Administration
- Oral (lozenge)
01
Overview
FP01 is a proprietary lozenge formulation of memantine hydrochloride developed for the treatment of cough. Memantine is an NMDA (N-methyl-D-aspartate) receptor antagonist, traditionally used in the management of Alzheimer's disease. In this formulation, it was investigated as an antitussive (cough suppressant), with studies focusing on its safety and pharmacokinetics in healthy volunteers and efficacy in subjects with cough due to upper respiratory tract infection[1][2][4].
- Other names
- FP 01FP01FP-01memantine hydrochloride lozenge
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on memantine lozenge FP01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on memantine lozenge FP01.